BIOTECH, STOCKS, TECHNOLOGY

John McCamant

Editor,

Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

Nektar Therapeutics (NKTR) announced that it has signed two deals to advance BEMPEG combos — one with Merck (MRK) and the other with SFJ Pharmaceuticals, explains John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
The most advanced clinical programs at Precigen (PGEN) — known as PRGN-3005 UltraCAR-T and PRGN-3006 UltraCAR-T — have both delivered proof of concept data in cancer patients recently, asserts biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.
Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, suggests John McCamant, an industry leading biotechnology expert and editor of The Medical Technology Stock Letter.
Esperion (ESPR) just reported financials ($3 million in net sales) with the stock under pressure as the company continues to struggle with the new drug launch during the COVID-19 crisis, explains John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter. 

John's Videos

John McCamant, editor of The Medical Technology Stock Letter, is known for helping investors pick biotech winners. Join this session to discover a unique investment opportunity in a repurposed Phase II pill, poised to treat Covid-19 by reducing viral load.
Biotech is providing innovative drugs and vaccines for Covod-19. Join John McCamant of the Medical Technology Stock Letter to help you identify the winners.
Join John McCamant, editor of the Medical Technology Stock Letter, to discover how from vaccines to new drugs, Covid-19 shines the spotlight biotech's ability to provide solutions.
With a Presidential election rapidly approaching, new opportunities are also rapidly emerging. The current market environment is particularly well suited for stock pickers-especially these expert panelists whose careers are devoted to uncovering the best opportunities available in even the most rapidly changing environment. Although nothing is a sure thing, these expert stock pickers will help you sort through the universe of stocks to identify the best opportunities, so you can profit no matter who wins the White House this November!



Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More